Transforming Tubulin Therapy for Brain Diseases
Breaking through the blood-brain barrier with breakthrough treatment.
Reglagene develops orally administered medicines for the treatment of brain diseases. Our first therapy, RGN6024, is a cancer therapy with best-in-class brain penetration, currently in preclinical development. With an experienced team of pharmaceutical industry professionals, Reglagene is poised to revolutionize the treatment of brain diseases.
Desert Angels is proud to be the leading angel group investor in Reglagene since 2018 from Seed to Series A, and the lead investor in the current Bridge Note.
